Stockreport

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

Galectin Therapeutics Inc.  (GALT) 
Last galectin therapeutics inc. earnings: 11/12 08:00 am Check Earnings Report
PDF In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value While there was a favorable trend for incidence of varices [Read more]